美诺华(603538.SH)子公司获得利奥西呱片药品注册证书

Core Viewpoint - Meihua (603538.SH) announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., has received the drug registration certificate for Liosiguat tablets from the National Medical Products Administration, indicating a significant regulatory approval for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) [1] Group 1 - The drug Liosiguat is approved for the treatment of CTEPH and PAH, which are serious conditions affecting pulmonary circulation [1]